Journal article

PRELIMINARY SAFETY DATA FROM PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B‐CELL MALIGNANCIES TREATED WITH THE NOVEL B‐CELL LYMPHOMA 2 (BCL2) INHIBITOR BGB‐11417

CY Cheah, E Verner, CS Tam, J Hilger, Y Gao, J Huang, D Simpson, S Opat

Hematological Oncology | Wiley | Published : 2021

DOI: 10.1002/hon.85_2881

University of Melbourne Researchers

Citation metrics

5Dimensions

Keywords

6.2 Cellular and Gene Therapies
Hematology
3211 Oncology and Carcinogenesis
Clinical Research
Cancer
Lymphatic Research
Lymphoma
3201 Cardiovascular Medicine and Haematology
Rare Diseases
Biotechnology
32 Biomedical and Clinical Sciences
Orphan Drug